H.C. Wainwright analyst Emily Bodnar initiated coverage of Autolus Therapeutics with a Buy rating and $9 price target. Th e firm says the company's obecabtagene autoleucel as a "pipeline-in-a-product," with potential to expand from rare oncology indications into treatment-refractory, B cell mediated, autoimmune diseases.
